Health
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy – News-Medical.net
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB…
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute for Quality and Efficiency in Health…
Continue Reading
-
Business22 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General23 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Noosa News9 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General22 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts